Expression and mutational analysis of TGF-β/Smads signaling in human cervical cancers

Kyung D. Ki, Seo Y. Tong, Chu Yeop Huh, Jong M. Lee, Seon Kyung Lee, Sung-Gil Chi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To define the molecular basis of TGF-β1 function in cervical carcinogenesis, we explored the expression and mutational status of TGF-β1, TGF-β1 receptors, and Smads, the regulators of the TGF-β1 signaling pathway, in human cervical cancers. Methods: Expression of TGF-β1, TGF-β1 receptors, and Smads transcripts were determined by quantitative reverse transcription-polymerase chain reaction (RT-PCR), and sequence alteration was analyzed using RT-PCR-single-strand conformation polymorphism (SSCP) analysis. Genomic levels of TGF-β1, TGF-β1 receptors and Smads was also measured by quantitative genomic PCR. Results: Abnormal overexpression of TGF-β1 and abnormal reduction of type II TGF-β1 receptor were identified in 36% (18 of 50) and 20% (10 of 50) of cervical cancer tissues, respectively. 22% (11 of 50) in Smad2 and 14% (7 of 50) in Smad4 revealed tumor specific mRNA reduction less than a half of normal means. In addition, no evidence for sequence alterations of the gene was found by RT-PCR-SSCP analysis. Conclusion: Our study demonstrates that disruption of TGF-β/Smad signaling pathway exist in human cervical cancer, suggesting that abnormal expressions of the member of TGF-β/Smad signaling pathway might contribute to the malignant progression of human cervical tumors via suppressing the tumor suppression function of TGF-β1 1's tumor suppression function.

Original languageEnglish
Pages (from-to)117-121
Number of pages5
JournalJournal of Gynecologic Oncology
Volume20
Issue number2
DOIs
Publication statusPublished - 2009 Jun 1

Fingerprint

Uterine Cervical Neoplasms
Reverse Transcription
Polymerase Chain Reaction
Neoplasms
Carcinogenesis
Messenger RNA
Genes

Keywords

  • Cervical cancer
  • Expression
  • TGF-β/Smads

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Expression and mutational analysis of TGF-β/Smads signaling in human cervical cancers. / Ki, Kyung D.; Tong, Seo Y.; Huh, Chu Yeop; Lee, Jong M.; Lee, Seon Kyung; Chi, Sung-Gil.

In: Journal of Gynecologic Oncology, Vol. 20, No. 2, 01.06.2009, p. 117-121.

Research output: Contribution to journalArticle

Ki, Kyung D. ; Tong, Seo Y. ; Huh, Chu Yeop ; Lee, Jong M. ; Lee, Seon Kyung ; Chi, Sung-Gil. / Expression and mutational analysis of TGF-β/Smads signaling in human cervical cancers. In: Journal of Gynecologic Oncology. 2009 ; Vol. 20, No. 2. pp. 117-121.
@article{ee3193ebd91a44d6892c4bf136b67458,
title = "Expression and mutational analysis of TGF-β/Smads signaling in human cervical cancers",
abstract = "Objective: To define the molecular basis of TGF-β1 function in cervical carcinogenesis, we explored the expression and mutational status of TGF-β1, TGF-β1 receptors, and Smads, the regulators of the TGF-β1 signaling pathway, in human cervical cancers. Methods: Expression of TGF-β1, TGF-β1 receptors, and Smads transcripts were determined by quantitative reverse transcription-polymerase chain reaction (RT-PCR), and sequence alteration was analyzed using RT-PCR-single-strand conformation polymorphism (SSCP) analysis. Genomic levels of TGF-β1, TGF-β1 receptors and Smads was also measured by quantitative genomic PCR. Results: Abnormal overexpression of TGF-β1 and abnormal reduction of type II TGF-β1 receptor were identified in 36{\%} (18 of 50) and 20{\%} (10 of 50) of cervical cancer tissues, respectively. 22{\%} (11 of 50) in Smad2 and 14{\%} (7 of 50) in Smad4 revealed tumor specific mRNA reduction less than a half of normal means. In addition, no evidence for sequence alterations of the gene was found by RT-PCR-SSCP analysis. Conclusion: Our study demonstrates that disruption of TGF-β/Smad signaling pathway exist in human cervical cancer, suggesting that abnormal expressions of the member of TGF-β/Smad signaling pathway might contribute to the malignant progression of human cervical tumors via suppressing the tumor suppression function of TGF-β1 1's tumor suppression function.",
keywords = "Cervical cancer, Expression, TGF-β/Smads",
author = "Ki, {Kyung D.} and Tong, {Seo Y.} and Huh, {Chu Yeop} and Lee, {Jong M.} and Lee, {Seon Kyung} and Sung-Gil Chi",
year = "2009",
month = "6",
day = "1",
doi = "10.3802/jgo.2009.20.2.117",
language = "English",
volume = "20",
pages = "117--121",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "2",

}

TY - JOUR

T1 - Expression and mutational analysis of TGF-β/Smads signaling in human cervical cancers

AU - Ki, Kyung D.

AU - Tong, Seo Y.

AU - Huh, Chu Yeop

AU - Lee, Jong M.

AU - Lee, Seon Kyung

AU - Chi, Sung-Gil

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Objective: To define the molecular basis of TGF-β1 function in cervical carcinogenesis, we explored the expression and mutational status of TGF-β1, TGF-β1 receptors, and Smads, the regulators of the TGF-β1 signaling pathway, in human cervical cancers. Methods: Expression of TGF-β1, TGF-β1 receptors, and Smads transcripts were determined by quantitative reverse transcription-polymerase chain reaction (RT-PCR), and sequence alteration was analyzed using RT-PCR-single-strand conformation polymorphism (SSCP) analysis. Genomic levels of TGF-β1, TGF-β1 receptors and Smads was also measured by quantitative genomic PCR. Results: Abnormal overexpression of TGF-β1 and abnormal reduction of type II TGF-β1 receptor were identified in 36% (18 of 50) and 20% (10 of 50) of cervical cancer tissues, respectively. 22% (11 of 50) in Smad2 and 14% (7 of 50) in Smad4 revealed tumor specific mRNA reduction less than a half of normal means. In addition, no evidence for sequence alterations of the gene was found by RT-PCR-SSCP analysis. Conclusion: Our study demonstrates that disruption of TGF-β/Smad signaling pathway exist in human cervical cancer, suggesting that abnormal expressions of the member of TGF-β/Smad signaling pathway might contribute to the malignant progression of human cervical tumors via suppressing the tumor suppression function of TGF-β1 1's tumor suppression function.

AB - Objective: To define the molecular basis of TGF-β1 function in cervical carcinogenesis, we explored the expression and mutational status of TGF-β1, TGF-β1 receptors, and Smads, the regulators of the TGF-β1 signaling pathway, in human cervical cancers. Methods: Expression of TGF-β1, TGF-β1 receptors, and Smads transcripts were determined by quantitative reverse transcription-polymerase chain reaction (RT-PCR), and sequence alteration was analyzed using RT-PCR-single-strand conformation polymorphism (SSCP) analysis. Genomic levels of TGF-β1, TGF-β1 receptors and Smads was also measured by quantitative genomic PCR. Results: Abnormal overexpression of TGF-β1 and abnormal reduction of type II TGF-β1 receptor were identified in 36% (18 of 50) and 20% (10 of 50) of cervical cancer tissues, respectively. 22% (11 of 50) in Smad2 and 14% (7 of 50) in Smad4 revealed tumor specific mRNA reduction less than a half of normal means. In addition, no evidence for sequence alterations of the gene was found by RT-PCR-SSCP analysis. Conclusion: Our study demonstrates that disruption of TGF-β/Smad signaling pathway exist in human cervical cancer, suggesting that abnormal expressions of the member of TGF-β/Smad signaling pathway might contribute to the malignant progression of human cervical tumors via suppressing the tumor suppression function of TGF-β1 1's tumor suppression function.

KW - Cervical cancer

KW - Expression

KW - TGF-β/Smads

UR - http://www.scopus.com/inward/record.url?scp=77953366381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953366381&partnerID=8YFLogxK

U2 - 10.3802/jgo.2009.20.2.117

DO - 10.3802/jgo.2009.20.2.117

M3 - Article

VL - 20

SP - 117

EP - 121

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 2

ER -